Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z1NY
|
|||
| Former ID |
DCL000073
|
|||
| Drug Name |
BMS214662
|
|||
| Synonyms |
BMV; BMS 214662; BMS-214662; (3R)-3-benzyl-1-(1H-imidazol-5-ylmethyl)-4-thiophen-2-ylsulfonyl-3,5-dihydro-2H-1,4-benzodiazepine-7-carbonitrile; (R)-1-((1H-imidazol-5-yl)methyl)-3-benzyl-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine-7-carbonitrile; 3-BENZYL-1-(1H-IMIDAZOL-4-YLMETHYL)-4-(THIEN-2-YLSULFONYL)-2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPINE-7-CARBONITRILE; 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 1 | [1], [2], [3] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Bristol-Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H23N5O2S2
|
|||
| Canonical SMILES |
C1C(N(CC2=C(N1CC3=CN=CN3)C=CC(=C2)C#N)S(=O)(=O)C4=CC=CS4)CC5=CC=CC=C5
|
|||
| InChI |
1S/C25H23N5O2S2/c26-13-20-8-9-24-21(11-20)15-30(34(31,32)25-7-4-10-33-25)23(12-19-5-2-1-3-6-19)17-29(24)16-22-14-27-18-28-22/h1-11,14,18,23H,12,15-17H2,(H,27,28)/t23-/m1/s1
|
|||
| InChIKey |
OLCWFLWEHWLBTO-HSZRJFAPSA-N
|
|||
| CAS Number |
CAS 195987-41-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
832412, 7886272, 10300222, 14786047, 14810473, 14908370, 36890361, 52133974, 56468423, 103418948, 103990510, 104639589, 128824716, 128824717, 134338776, 134340794, 135269826, 137134982, 141546400, 142188266, 162256591, 179113909, 184528584, 198961168, 223786561, 226472148, 249565706, 251963014, 252215022
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Farnesyl protein transferase (Ftase) | Target Info | Modulator | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8026). | |||
| REF 2 | ClinicalTrials.gov (NCT00006242) BMS-214662 in Treating Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT00022529) BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 4 | Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia. 2004 Oct;18(10):1599-604. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.